Blog

M. Bilal Abid: Reporting data on the efficacy and safety of bispecific CAR T-cell therapy in hematological malignancies

M. Bilal Abid/LinkedIn

Nov 10, 2024, 04:17

M. Bilal Abid: Reporting data on the efficacy and safety of bispecific CAR T-cell therapy in hematological malignancies

M. Bilal Abid, Research Fellow in Cancer Therapeutics at MD Anderson Cancer Center, shared on LinkedIn about recent paper by him as first, titled “CT-115 Efficacy and Safety of Dual Antigen Targeting Chimeric Antigen Receptor T-cells in Hematologic Malignancies: A Meta-analysis of Clinical Trials” published on Science Direct.

Authors: Muhammad Bilal Abid, Linus Zhen, Ryan Ruiyang Ling, Bingwen Eugene Fan

“Dual antigen targeting CAR T-cells simultaneously target 2 B-cell surface antigens to overcome antigen escape and expression heterogeneity in tumors. Since early-phase, investigational clinical trials are typically small, we conducted a systematic review and meta-analysis of available studies reporting data on the efficacy and safety of bispecific CAR T-cell therapy.

We examined outcomes stratified by the CAR-T construct (CD19/20, CD19/22, CD19/BCMA, CD3z/CD28, CD19/7, CS1-BCMA, BCMA/CD38) and the underlying disease.

The results are timely as CAR products swiftly move beyond oncology space!”

Muhammad Bilal Abid is a Research Fellow in Cancer Therapeutics at MD Anderson Cancer Center. He has also serves as a Senior Clinical Fellow in Hematology/Oncology at The University of Texas Health Science Center at Houston (UTHealth Houston). His work focuses on scientific research, clinical trials, and the development of protocols related to Investigational New Drug (IND) and New Drug Application (NDA) processes in hematology/oncology and cellular therapy.